Prognosis and prognostic factors in sporadic inclusion body myositis

Acta Neurologica Scandinavica

Volumn 125, Issue 5, 2012, Pages 353-358

  Lindberg, C ^a   Oldfors, A ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Inclusion body myositis; Myometry; Prognosis

Indexed keywords

AZATHIOPRINE; CREATINE KINASE; CYCLOSPORIN A; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; COHORT ANALYSIS; CREATINE KINASE BLOOD LEVEL; DETERIORATION; DYNAMOMETER; ELBOW; ELBOW FLEXION; FEMALE; FOLLOW UP; HIP; HUMAN; KNEE FUNCTION; MAJOR CLINICAL STUDY; MALE; MUSCLE STRENGTH; MYOSITIS; PROGNOSIS; QUADRICEPS FEMORIS MUSCLE; SPORADIC INCLUSION BODY MYOSITIS; TREATMENT RESPONSE;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MYOSITIS, INCLUSION BODY;

EID: 84859427350     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01584.x     Document Type: Article

References (17)

1. Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis. Observations in 40 patients. Brain 1989;112:727-47.
2. Lindberg C, Persson L, Björkander J, Oldfors A. Inclusion body myositis - clinical, morphological, physiological and laboratory findings in 18 cases. Acta Neurol Scand 1994;89:123-31.
3. Badrising UA, Maat-Schieman ML, Van Houwlingen JC, et al. Clinical features and clinical course of the disease in 64 patients. J Neurol 2005;252:1448-54.
4. Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve 2000;23:970-2.
5. Needham M, Corbett A, Day T, Christiansen F, Fabian V, Mastaglia FL. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neuroscience 2008;15:1350-3.
6. Engel AG, Arahata K. Mononuclear cells in myopathies: quantification of functionally distinct subsets, recognition of antigen specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986;17:704-21.
7. Askanas V, Engel WK. Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging. Scand J Rheumatol 1998;27:389-405.
8. Felice KJ, North WA. Inclusion Body Myositis in Connecticut. Observation in 35 patients during an 8-year period. Medicine 2001;80:320-7.
9. Rose MR, McDermott MP, Thornton CA, Palenski C, Martens WB, Griggs RC. A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology 2001;57:548-50.
10. Peng A, Koffman BM, Malley JD, Dalakas MC. Disease progression in sporadic inclusion body myositis: observations in 78 patients. Neurology 2000;55:296-8.
11. Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003;61:260-2.
12. Dalakas M, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009;132:1536-44.
13. Leff RL, Miller FW, Hicks J, Fraser DD, Plotz PH. The treatment of inclusion body myositis - a retrospective review and a randomized, prospective trial of immunosuppressive therapy. Medicine 1993;72:225-35.
14. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48:712-6.
15. Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double blind, placebo-controlled study. J Neurol 2000;247:22-8.
16. Badrising UA, Maat-Schieman ML, Zwinderman AH, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol 2002;51:369-72.
17. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.